European Regulators Urge Open Drug Trial Data for All

Kermit Cole
0
27

In a paper published in PLoS Medicine, representatives of regulatory agencies in the U.K., France, and the Netherlands argue that clinical trial data should not be considered commercial confidential information. While adequate protection of privacy for study subjects is important, excessive protection does not serve the common good or, in fact, the intent of their participation. Full clinical trial reports should be made available to enable independent re-analysis of drugs’ benefits and risks, they argue.

Article → 

Related Items:
How drug companies continue to hide the true story of Tamiflu and other drugs from the American public
Drug Data Shouldn’t Be Secret
Neuraminidase inhibitors—the story behind the Cochrane Review
More on the need for data sharing — the Tamiflu example
Drug Data Shouldn’t Be Secret

Previous articleSocial Environment Moderates the Link Between Family and Psychosis
Next articleScaremongerers of the World Unite
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected]